Friday, 22 Mar 2019

You are here

NK cells and a Potential Role in the Development of PsA vs PsC (Cutaneous Psoriasis)

Human NK cells express multiple receptors that interact with HLA class I molecules which, in turn, suppy peptides that bind HLA-E to form CD94/NKG2A NK receptor ligands. These peptides correspond to -22 to -14 residues in the leader sequences of HLA-A, HLA-B and HLA-C binding to the HLA-E site. Methionine – 21 delivers functional peptides in stark contrast to threonine – 21 which does not. This functional dimorphism allows for division into three groups: -21M/M, -21M/T and -21T/T with respectively decreasing potency of the NKCD94/NKG2A+ receptor. Dr. Chandran et al aimed to determine if these particular haplotypes served as differences between the connection between the HLA class 1 alleles and Psoriatic disease vs the normal population.

Six hundred and sixty four PsA patients, 1155 PsC (cutaneous only Psoriasis) patients vs 3118 controls were studied. One thousand one hundred and seventy seven PsA patients, 659 PsC patients and 1096 controls were self- reported European ethnicity from a single center cohort in Toronto. SNP2HLA was used represent HLA class 1 alleles. Analyses using logistical regression to determine association between HLA B-21 amino acid polymorphisms and different phenotypes in PsC vs controls, PsA vs controls, and PsA vs PsC. Sex and population stratification were used as covariates. This study used reverse line blot techniques and sequence specific oligonucleotide (SSO) probes to type HLA and all analyses were conditioned on HLA B27.

This study found that the PsC patient cohort had significantly lower prevalence of -21M compared to PsA and control patients.

In conclusion, this is one study that indicates a potential NK cell pathogenesis in the development of PsA and shows a possible genetic marker that can differentiate PsA from PsC.

Chandran V, Li Q, Machhar R, Abji F, Ye JY, Nair R, Stuart P, Oikonomopoulou K, Elder JT, Gladman DD, Rahman P. −21 HLA-Class I Dimorphism Differentiates Psoriatic Arthritis (PsA) from Psoriasis without Psoriatic Arthritis (PsC) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/%e2%88%9221-hla-class-i-dimorphism-dif.... Accessed October 18, 2018.

 

https://acrabstracts.org/abstract/%E2%88%9221-hla-class-i-dimorphism-dif...

Add new comment

More Like This

Biologic Agents have Equal Efficacy in Enthesitis and Dactylitis

A systematic review has shown that TNF inhibitors (TNFi) are equaled in efficacy by other biologic agents (ustekinumab, secukinumab, and ixekizumab) in psoriatic arthritis (PsA) patients with in dactylitis and enthesitis.

The literature review analyzed datafrom randomized controlled trials (RCTs) with TNFi (infliximab, golimumab, adalimumab), antiinterleukin- 12/23 (ustekinumab) and anti-interleukin-17 (secukinumab, ixekizumab).

Dual IL-17 Inhibitor in Psoriasis Succeeds

Patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of interleukin (IL)-17, data from a randomized trial showed. 

AAD/NPF Guidelines on Biologic Use in Psoriasis

Menter and colleagues from the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) have published their expert consensus guidelines for the use of biologics in psoriasis.

Dermatology Guidelines for Psoriatic Comorbidities

The JAAD has published joint guidelines from the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) on the approach, management and dermatolgist roles for select comorbid conditions. 

Early TNF inhibition in Early Psoriatic Arthritis

A small, double-blind, randomised, placebo-controlled trial in early psoriatic arthritis (PsA) has shown that first-line use of golimumab and methotrexate (MTX) is superior to MTX alone in inducing remission in PsA.